- Home
- NGNE vs AQST Comparison
NGNE vs AQST Comparison
Compare NGNE & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- AQST
- Stock Information
- Founded
- NGNE 2003
- AQST 2004
- Country
- NGNE United States
- AQST United States
- Employees
- NGNE N/A
- AQST N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- NGNE Health Care
- AQST Health Care
- Exchange
- NGNE Nasdaq
- AQST Nasdaq
- Market Cap
- NGNE 325.3M
- AQST 272.9M
- IPO Year
- NGNE N/A
- AQST 2018
- Fundamental
- Price
- NGNE $22.72
- AQST $4.15
- Analyst Decision
- NGNE Strong Buy
- AQST Strong Buy
- Analyst Count
- NGNE 7
- AQST 7
- Target Price
- NGNE $41.86
- AQST $11.29
- AVG Volume (30 Days)
- NGNE 216.3K
- AQST 1.2M
- Earning Date
- NGNE 08-08-2025
- AQST 08-05-2025
- Dividend Yield
- NGNE N/A
- AQST N/A
- EPS Growth
- NGNE N/A
- AQST N/A
- EPS
- NGNE N/A
- AQST N/A
- Revenue
- NGNE $925,000.00
- AQST $54,228,000.00
- Revenue This Year
- NGNE N/A
- AQST N/A
- Revenue Next Year
- NGNE N/A
- AQST $51.62
- P/E Ratio
- NGNE N/A
- AQST N/A
- Revenue Growth
- NGNE N/A
- AQST 5.29
- 52 Week Low
- NGNE $6.88
- AQST $2.12
- 52 Week High
- NGNE $74.49
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- NGNE 60.64
- AQST 61.40
- Support Level
- NGNE $20.80
- AQST $3.96
- Resistance Level
- NGNE $23.88
- AQST $4.38
- Average True Range (ATR)
- NGNE 1.44
- AQST 0.23
- MACD
- NGNE 0.09
- AQST -0.01
- Stochastic Oscillator
- NGNE 72.83
- AQST 60.23
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.